
Home Chapter Home Jobs Conferences Fellowships Books
Skin-Melanocytic Tumors
Sentinel node biopsy for melanoma
Last major update: November 2008 - next update November 2009
Revised: 11 July 2009
Author: Nat Pernick, M.D., PathologyOutlines.com, Inc.
Copyright: (c) 2002-2009, PathologyOutlines.com, Inc.
Definition
=========================================================================
● Sentinel lymph node is defined as first extracutaneous target of lymphogenous tumor cell spread and the potential source of subsequent lymph node metastases and distant metastases
● Lymphatic mapping and sentinel lymph node biopsy are widely used for staging
Recommendations
=========================================================================
● Use for thick (Semin Diagn Pathol 2008;25:86) and thin melanomas (1 mm thick or less, Arch Surg 2008;143:892)
● Tumor in sentinel node by H&E predicts recurrence (Mod Path 2007;20:427), usually leads to dissection of lymph nodes in affected nodal basin (Ann Surg Oncol 2008;15:1566), which reduces recurrence (Curr Treat Options Oncol 2008 Nov 8 [Epub ahead of print])
● Measuring antimony (originating from antimony sulfide colloid) can confirm sentinel nature of node (Mod Path 2004;17:1191)
Treatment and prognosis
=========================================================================
● Predictors of positive sentinel nodes: Breslow thickness > 1 mm (Int J Surg 2008;6:205); lymphatic invasion using D2-40, ulceration (Arch Dermatol 2008;144:462), younger age (Ann Surg Oncol 2008;15:630)
● Predictors of positive nonsentinel nodes in sentinel node positive patients (occurs in 20-35%): amount of tumor in sentinel node, Breslow thickness of primary melanoma, density of dendritic WBCs in sentinel node paracortex (Mod Path 2004;17:747); also perinodal intralymphatic tumor (Ann Surg Oncol 2008;15:1723), depth of invasion in sentinel node (Ann Surg Oncol 2008;15:1202)
● S100 and NKI-C3 are most sensitive stains for nodal metastases, but are nonspecific; MART1 is most specific (AJSP 2001;25:1039)
● S100 and MART1 together are recommended (Hum Path 2004;35:217)
● Intraoperative touch imprints may be accurate (Anticancer Res 2008;28:465)
● Patients with triple negative (H&E, S100/HMB45, RT-PCR) nodes have a markedly improved survival (Mod Path 2008;21:438)
● Micrometastasis: single metastasis < 2 mm not associated with metastases in non-sentinel nodes (J Surg Oncol 2008;98:46)
● RT-PCR: prognostic significance of melanocytic mRNA in histologically negative nodes is controversial (significant-APMIS 2008;116:199, not significant-Mod Pathol 2007;20:427)
● Recommended protocols for sentinel nodes:
● (a) 3 levels at 250 micrometer intervals, each level has 1 section stained with H&E, S-100 and HMB-45 (AJSP 2005;29:305), OR
● (b) 2 H&E sections, S100 and HMB45 (AJSP 2003;27:1197)
Clinical images
=========================================================================
Schematic of intraoperative lymphatic mapping and sentinel node
Micro images
=========================================================================
Metastatic tumor by RT-PCR, S100 staining of nevus cells
H&E, S100, HMB45 and melanoma cells
HMB45 Tattoo pigment (not tumor)
Videos
=========================================================================
● Wide excision and sentinel node mapping
Differential diagnosis
=========================================================================
● Benign nevus cells - usually in capsule, also parenchyma, no atypia, MART1+, S100+, HMB45-, Ki-67 neg (AJSP 2002;26:1351, AJSP 2003;27:673)
● Histiocytes - no atypia
● Tattoo pigment (Dermatol Online J 2005;11(1):14)
Additional references
=========================================================================
End of Skin-Melanocytic Tumors > Sentinel node biopsy for melanoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must also be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by Copyright, (c) 2001-2009, PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions.